A fenofibrate composition for oral administration comprising: (a) particles of fenofibrate or a salt thereof, wherein at least 99% of the fibrate particles by weight have a particle size of less than 500nm or at least 50% of the fibrate particles by weight have a particle size of less than 350nm; and (b) associated with the surface thereof, a surface stabilizer composition comprising hypromellose, docusate sodium, and sodium lauryl sulfate, wherein the composition does not comprise PEG-derivatized vitamin E, and wherein the composition does not produce significantly different absorption levels when administered underfed as compared to fasting conditions wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, wherein "bioequivalency" is established by: (a) a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both Cmax and AUC under USFDA regulatory guidelines or (b) a 90% Confidence Interval (CI) for AUC of between 0.80 and 1.25 and a 90% Cl for Cmax of between 0.70 to 1.43 under the European EMEA regulatory guidelines. (a) particles of fenofibrate or a salt thereof, wherein at least 99% of the fibrate particles by weight have a particle size of less than 500nm or at least 50% of the fibrate particles by weight have a particle size of less than 350nm; and (b) associated with the surface thereof, a surface stabilizer composition comprising hypromellose, docusate sodium, and sodium lauryl sulfate, wherein the composition does not comprise PEG-derivatized vitamin E, and wherein the composition does not produce significantly different absorption levels when administered underfed as compared to fasting conditions wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, wherein "bioequivalency" is established by: (a) a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both Cmax and AUC under USFDA regulatory guidelines or (b) a 90% Confidence Interval (CI) for AUC of between 0.80 and 1.25 and a 90% Cl for Cmax of between 0.70 to 1.43 under the European EMEA regulatory guidelines. wherein the composition does not comprise PEG-derivatized vitamin E, and wherein the composition does not produce significantly different absorption levels when administered underfed as compared to fasting conditions wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, wherein "bioequivalency" is established by: (a) a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both Cmax and AUC under USFDA regulatory guidelines or (b) a 90% Confidence Interval (CI) for AUC of between 0.80 and 1.25 and a 90% Cl for Cmax of between 0.70 to 1.43 under the European EMEA regulatory guidelines. (a) a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both Cmax and AUC under USFDA regulatory guidelines or (b) a 90% Confidence Interval (CI) for AUC of between 0.80 and 1.25 and a 90% Cl for Cmax of between 0.70 to 1.43 under the European EMEA regulatory guidelines. <EOS>